2014～2018年中国宫颈癌临床实践指南的方法学质量评价  

Methodological quality assessment of clinical practice guidelines for cervical cancer in China from 2014 to 2018

作　　者：胡菲菲 何俊勇[2] 何礼霞 曹炎培 刘筠 HU Feifei;HE Junyong;HE Lixia;CAO Yanpei;LIU Yun(Department of gynaecology and obstetrics,Shenzhen University General Hospital,Shenzhen University Clinical Medical Academy,Shenzhen,518055,P.R.China;Health Management Center of West China Hospital,Sichuan University,Chengdu,610041,P.R.China)

机构地区：[1]深圳大学总医院妇产科,深圳大学临床医学科学院,广东深圳518055 [2]四川大学华西医院健康管理中心,成都610041

出　　处：《中国循证医学杂志》2019年第8期989-993,共5页Chinese Journal of Evidence-based Medicine

基　　金：深圳大学自然科学基金(编号：0000040560)

摘　　要：目的评价2014~2018年发表的中国宫颈癌临床实践指南的质量。方法计算机检索CNKI、WanFang Data、CBM、VIP、医脉通、美国国立临床诊疗指南数据库、PubMed、The Cochrane Library和EMbase数据库,搜集中国制订的宫颈癌临床实践指南,检索时限为2014年1月1日至2018年12月31日。由4名评价员按照纳入和排除标准独立筛选文献,并采用AGREEⅡ工具评价纳入指南的方法学质量。结果共纳入9部指南。各领域平均得分:范围和目的为75.47%、参与人员为35.09%、制订的严谨性为43.70%、清晰性为87.74%、应用性为80.76%、编辑独立性为0%。结论我国宫颈癌临床实践指南质量有待于进一步提高。Objectives To assess the methodological quality of clinical practice guidelines of cervical cancer in China published from 2014 to 2018.Methods CNKI,WanFang Data,CBM,VIP,Medlive.cn,the National Guideline Clearinghouse,PubMed,The Cochrane Library and EMbase were searched for cervical cancer clinical practice guidelines published in China from January 1st,2014 to December 31st,2018.Four reviewers searched and selected the literature independently according to the inclusion and exclusion criteria and assessed the methodological quality of the included guidelines by using AGREEⅡ.Results A total of 9 guidelines were included.The average score for each area was:scope and purpose 75.47%,stakeholders’involvement 35.09%,the rigor of development 43.70%,clarity of presentation 87.74%,applicability 80.76%,and editorial independence 0%.Conclusions The quality of cervical cancer clinical practice guidelines in China requires further improvement.

关 键 词：宫颈癌 临床实践指南 共识 质量评价 AGREEⅡ 

分 类 号：R737.33[医药卫生—肿瘤]